Julie C Fitzgerald1, Nicole R Zane2, Adam S Himebauch3, Michael D Reedy4, Kevin J Downes2,5, Alexis A Topjian3, Susan L Furth5, Neal J Thomas6, Marc H Scheetz7, Athena F Zuppa3,2. 1. Department of Anesthesiology and Critical Care Medicine, Children's Hospital of Philadelphia and The University of Pennsylvania Perelman School of Medicine, 3401 Civic Center Blvd, 6th Floor Wood Building, Room 6117, Philadelphia, PA, 19104, USA. fitzgeraldj@email.chop.edu. 2. Center for Clinical Pharmacology, Children's Hospital of Philadelphia, Philadelphia, PA, USA. 3. Department of Anesthesiology and Critical Care Medicine, Children's Hospital of Philadelphia and The University of Pennsylvania Perelman School of Medicine, 3401 Civic Center Blvd, 6th Floor Wood Building, Room 6117, Philadelphia, PA, 19104, USA. 4. Department of Pharmacy, Nemours/Alfred I. duPont Hospital for Children, Wilmington, DE, USA. 5. Department of Pediatrics, Children's Hospital of Philadelphia and The University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. 6. Department of Pediatrics, Penn State Hershey Children's Hospital, Penn State University College of Medicine, Hershey, PA, USA. 7. Department of Pharmacy Practice, Pharmacometric Center of Excellence, Midwestern University, Downers Grove, IL, USA.
Abstract
BACKGROUND: Acute kidney injury (AKI) commonly occurs after cardiac arrest. Those subsequently treated with vancomycin are at additional risk for drug-induced kidney injury. OBJECTIVE: We aimed to determine whether opportunities exist for improved drug monitoring after cardiac arrest. METHODS: This was a retrospective cohort study of children aged 30 days-17 years treated after cardiac arrest in an intensive care unit from January 2010 to September 2014 who received vancomycin within 24 h of arrest. Vancomycin dosing and monitoring were compared between those with and without AKI, with AKI defined as pRIFLE (pediatric risk, injury, failure, loss, end-stage renal disease) stage 2-3 AKI at day 5 using Schwartz formula-calculated estimated glomerular filtration rate (eGFR). RESULTS: Of 43 children, 16 (37%) had AKI at day 5. Age, arrest duration, median time to first vancomycin dose, and the number of doses before and time to first vancomycin concentration measurement were similar between groups. Children with AKI had higher initial vancomycin concentrations than those without AKI (median 16 vs. 7 mg/L; p = 0.003). A concentration was not measured before the second dose in 44% of children with AKI. Initial eGFR predicted day 5 AKI. In children with AKI, the initial eGFR was lower in those with than those without a concentration measurement before the second dose (29 mL/min/1.73 m2 [interquartile range (IQR) 23-47] vs. 52 [IQR 50-57]; p = 0.03) but well below normal in both. CONCLUSIONS: In children with AKI after cardiac arrest, decreased vancomycin clearance was evident early, and early monitoring was not performed universally in those with low initial eGFR. Earlier vancomycin therapeutic drug monitoring is indicated in this high-risk population.
BACKGROUND:Acute kidney injury (AKI) commonly occurs after cardiac arrest. Those subsequently treated with vancomycin are at additional risk for drug-induced kidney injury. OBJECTIVE: We aimed to determine whether opportunities exist for improved drug monitoring after cardiac arrest. METHODS: This was a retrospective cohort study of children aged 30 days-17 years treated after cardiac arrest in an intensive care unit from January 2010 to September 2014 who received vancomycin within 24 h of arrest. Vancomycin dosing and monitoring were compared between those with and without AKI, with AKI defined as pRIFLE (pediatric risk, injury, failure, loss, end-stage renal disease) stage 2-3 AKI at day 5 using Schwartz formula-calculated estimated glomerular filtration rate (eGFR). RESULTS: Of 43 children, 16 (37%) had AKI at day 5. Age, arrest duration, median time to first vancomycin dose, and the number of doses before and time to first vancomycin concentration measurement were similar between groups. Children with AKI had higher initial vancomycin concentrations than those without AKI (median 16 vs. 7 mg/L; p = 0.003). A concentration was not measured before the second dose in 44% of children with AKI. Initial eGFR predicted day 5 AKI. In children with AKI, the initial eGFR was lower in those with than those without a concentration measurement before the second dose (29 mL/min/1.73 m2 [interquartile range (IQR) 23-47] vs. 52 [IQR 50-57]; p = 0.03) but well below normal in both. CONCLUSIONS: In children with AKI after cardiac arrest, decreased vancomycin clearance was evident early, and early monitoring was not performed universally in those with low initial eGFR. Earlier vancomycin therapeutic drug monitoring is indicated in this high-risk population.
Authors: Tara M Neumayr; Jeff Gill; Julie C Fitzgerald; Avihu Z Gazit; Jose A Pineda; Robert A Berg; J Michael Dean; Frank W Moler; Allan Doctor Journal: Pediatr Crit Care Med Date: 2017-10 Impact factor: 3.624
Authors: Nicole R Zane; Michael D Reedy; Marc R Gastonguay; Adam S Himebauch; Evan Z Ramsey; Alexis A Topjian; Athena F Zuppa Journal: Pediatr Crit Care Med Date: 2017-07 Impact factor: 3.624
Authors: Ryan W Morgan; Julie C Fitzgerald; Scott L Weiss; Vinay M Nadkarni; Robert M Sutton; Robert A Berg Journal: J Crit Care Date: 2017-03-31 Impact factor: 3.425
Authors: A Akcan-Arikan; M Zappitelli; L L Loftis; K K Washburn; L S Jefferson; S L Goldstein Journal: Kidney Int Date: 2007-03-28 Impact factor: 10.612
Authors: Michael Zappitelli; Chirag R Parikh; Ayse Akcan-Arikan; Kimberley K Washburn; Brady S Moffett; Stuart L Goldstein Journal: Clin J Am Soc Nephrol Date: 2008-04-16 Impact factor: 8.237
Authors: George J Schwartz; Alvaro Muñoz; Michael F Schneider; Robert H Mak; Frederick Kaskel; Bradley A Warady; Susan L Furth Journal: J Am Soc Nephrol Date: 2009-01-21 Impact factor: 10.121
Authors: David T Selewski; Timothy T Cornell; Michael Heung; Jonathan P Troost; Brett J Ehrmann; Rebecca M Lombel; Neal B Blatt; Kera Luckritz; Sue Hieber; Robert Gajarski; David B Kershaw; Thomas P Shanley; Debbie S Gipson Journal: Intensive Care Med Date: 2014-07-31 Impact factor: 17.440
Authors: Omar Alkandari; K Allen Eddington; Ayaz Hyder; France Gauvin; Thierry Ducruet; Ronald Gottesman; Véronique Phan; Michael Zappitelli Journal: Crit Care Date: 2011-06-10 Impact factor: 9.097
Authors: Stan J F Hartman; Roger J Brüggemann; Lynn Orriëns; Nada Dia; Michiel F Schreuder; Saskia N de Wildt Journal: Clin Pharmacokinet Date: 2020-02 Impact factor: 6.447